Skip to content
Open access

A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge

Oct 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 76 references
Medicine

TL;DR

A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling.

Abstract

Introduction Chikungunya virus (CHIKV) is primarily transmitted to humans through bites of infected Aedes mosquitoes, causing febrile illness as well as acute or chronic arthritis. With increasing reports in previously non-endemic regions, it poses an emerging threat to public health and a growing risk to travelers. Despite the recent approval of live-attenuated and virus-like particle-based vaccines, a safe, efficacious, and cost-effective vaccine remains urgently needed. The envelope glycoproteins E1 and E2, which play crucial roles in viral attachment and entry, are the major immunodominant structural proteins and can effectively elicit protective antibodies. Methods We engineered mammalian cells to produce the ectodomains of the E1 and E2 glycoproteins and evaluated the protective efficacy of the resulting vaccine formulations in vivo. Results A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling. Discussion These findings demonstrate the potential of this vaccine candidate against CHIKV and warrant its further development.

Read PDF

Similar papers

Open access Sep 2026

Combination of live-attenuated and adenovirus-based vaccines provides immediate and durable protection against Yersinia pestis in mice

Mice immunized with both strategies were completely protected and elicited robust and durable humoral and cellular immune responses through 6 months, and these vaccines and strategies are suitable for reactive (emergency) and preventive (in endemic regions) use.

Emily K. Hendrix, J. Sha, Paul B. Kilgore et al. · 0 citations
Open access Nov 2026

The mRNA-LNP Vaccine Encoding Viral VP2 Confers Effective Protection Against Very Virulent Infectious Bursal Disease Virus (vvIBDV)

Infectious bursal disease (IBD) is an acute, highly contagious, and immunosuppressive disease of poultry caused by the infectious bursal disease virus (IBDV). For more than 30 years, the very virulent IBDV (vvIBDV) characterized by high mortality has been widely prevalent worldwide, inflicting considerable economic los...

Yu-Long Zhang, Zi-Wen Wu, Hang-Bo Yu et al. · 0 citations
Open access Oct 2026

Cross-protection of wildtype and vaccine-derived chikungunya virus antibodies against chikungunya and Mayaro viruses in mice

This study assessed antibody-mediated protection following vaccination or natural infection by passively immunizing transiently immunocompromised mice with graded doses of pooled immune sera before challenge with two CHIKV genotypes or the related Mayaro virus (MAYV).

Konrad M. Wesselmann, Léa Luciani, M. Cochin et al. · 0 citations
Open access Oct 2026

Dual-Antigen CCHFV Vaccine Induces Neutralizing Immunity and Protection Against Lethal Challenge

It is demonstrated that systematic antigen screening combined with genetic vaccine platforms can identify a potent multi-antigen CCHF vaccine candidate and induced Gc-specific neutralizing antibodies and T-cell responses against both NP and Gc.

Jing-Yi Yan, Lara Sweetapple, Christian An Bính Nordentoft et al. · 0 citations
Open access Sep 2026

An Adenoviral‐Vectored Tp0326 Vaccine Elicits Robust Functional Antibodies to Prevent Treponema pallidum Dissemination in a Rabbit Model

ABSTRACT Vaccination can prevent congenital infections by inducing antibodies that block transplacental pathogen transmission. For syphilis, which is caused by Treponema pallidum (T. pallidum), no vaccine is yet available to halt its vertical spread to fetuses. Here, we designed an adenovirus‐vectored vaccine expressin...

Yin-Bo Jiang, Xin-Yuan Li, Li-Xia Huang et al. · 0 citations
Oct 2026

Protective efficacy of bacterial sialidase-based intranasal inactivated avian influenza vaccine against H5N1 infection in poultry.

The avian influenza virus (AIV) poses a serious threat to the poultry industry, leading to substantial economic losses and having the potential to cause severe zoonotic diseases worldwide. The development of mucosal vaccines has prompted greater attention due to their ability to mimic the natural infection process and...

R. S. Kurnia, C. M. Nugroho, O. M. Silaen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.